Bentamapimod 10 mg | 95.21%
TargetMol
Bentamapimod
Search Results
Timapiprant 5 mg | 99.89%
TargetMol
OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist (IC50: 13 nM).
More Information Supplier PageTimapiprant
Timapiprant 50 mg | 99.89%
TargetMol
OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist (IC50: 13 nM).
More Information Supplier PageTimapiprant
Timapiprant 25 mg | 99.89%
TargetMol
OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist (IC50: 13 nM).
More Information Supplier PageTimapiprant
Timapiprant 10 mg | 99.89%
TargetMol
OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist (IC50: 13 nM).
More Information Supplier PageTimapiprant
GSK2801 10 mg | 99.88%
TargetMol
GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
More Information Supplier PageGSK2801
GSK2801 5 mg | 99.88%
TargetMol
GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
More Information Supplier PageGSK2801
IC261 10 mg | 99.86%
TargetMol
IC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.
More Information Supplier PageIC261
IC261 50 mg | 99.86%
TargetMol
IC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.
More Information Supplier PageIC261
IC261 5 mg | 99.86%
TargetMol
IC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.
More Information Supplier PageIC261